Keyphrases
Lupus
71%
Systemic Lupus Erythematosus Patient
45%
Systemic Lupus Erythematosus
44%
Peruvian
31%
Health-related Quality of Life
31%
SLE Disease Activity Index (SLEDAI)
29%
Remission
25%
Damage Accrual
23%
Latin American
23%
Patient Data
19%
Age at Diagnosis
18%
Disease Duration
16%
Multivariable
15%
Damage Index
15%
Disease Activity
15%
Confidence Interval
14%
Rheumatology
14%
Granulomatosis with Polyangiitis
13%
American College of Rheumatology
12%
Systemic Lupus International Collaborating Clinics
11%
Prednisone
9%
Tertiary Care Hospital
9%
Low Disease Activity
9%
ANCA-associated Vasculitis
9%
Poor Health
9%
Systematic Literature Review
9%
Homocysteine Levels
9%
T Cells
9%
CD4+CD28null
9%
Low Disease Activity State
9%
Serum Uric Acid
9%
Renal Damage
9%
SLICC
8%
Microscopic Polyangiitis
8%
Hospitalization
8%
Disease Activity Score
7%
Demographic Characteristics
7%
Lupus Low Disease Activity State (LLDAS)
7%
Multivariable Model
7%
COVID-19
7%
Hazard Ratio
7%
Emotional Health
6%
Activity State
6%
Immunosuppressive Drugs
6%
Classification Criteria
6%
Regression Analysis
6%
Risk Factors
6%
Cox Regression Model
5%
Comorbidity
5%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
5%
Medicine and Dentistry
Systemic Lupus Erythematosus
97%
Lupus Erythematosus
75%
Disease Activity
39%
Quality of Life
30%
SLEDAI
25%
Rheumatology
24%
Patient-Data
19%
Disease Duration
16%
ANCA Associated Vasculitis
14%
Kidney Injury
14%
Granulomatosis with Polyangiitis
13%
Rheumatoid Arthritis
10%
Rheumatic Disease
9%
Homocysteine
9%
Uric Acid
9%
COVID-19
9%
Prednisone
9%
Lupus Nephritis
9%
Microscopic Polyangiitis
8%
Antimalarial Agent
8%
Disease
7%
Glucocorticoid
7%
Hazard Ratio
6%
Immunosuppressive Drug
6%
Prevalence
6%
Patient-Reported Outcome
6%
Proteinuria
6%
Emotional Stability
5%
Rituximab
5%
Proportional Hazards Model
5%
Creatinine
5%
Vasculitis
5%
Hand-Schüller-Christian Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
100%
Disease Activity
51%
Remission
27%
Disease Duration
16%
Wegener Granulomatosis
14%
ANCA Associated Vasculitis
14%
Disease
12%
Rheumatic Disease
9%
Homocysteine
9%
Uric Acid
9%
Kidney Injury
9%
Microscopic Polyangiitis
9%
Rheumatoid Arthritis
7%
Glucocorticoid
7%
Prednisone
7%
Immunosuppressive Agent
7%
Vasculitis
6%
Comorbidity
6%
Lupus Erythematosus Nephritis
6%
Eosinophilic Granuloma
5%
Prevalence
5%
Infection
5%
Lung Injury
5%
Rituximab
5%
Antimalarial Agent
5%
Clinical Feature
5%
